Sydney, Feb 23, 2026, 17:07 AEDT — Markets moving after hours.
CSL Ltd (CSL.AX) dropped 3.8% to A$147.38 on Monday, touching a 52-week low of A$147.18 during the session after closing at A$153.27 previously.
CSL stands as a heavyweight in Australia’s healthcare sector, and its performance tends to sway the group. On Monday, shares slipped even as the company issued little more than some filings. Investors treated CSL as something of a risk gauge heading into the following session.
The S&P/ASX 200 slipped 0.61% at the close, weighed down by declines across healthcare, tech and real estate stocks that easily outweighed strength in other sectors.
Overseas markets wobbled after the U.S. Supreme Court overturned President Donald Trump’s emergency tariffs, leaving traders in the dark on what rates would stick—and when. “The tariff landscape is now more uncertain than before, uncertainty is not good news for any economy or market,” said Rodrigo Catril, senior FX strategist at National Australia Bank. Reuters
CSL disclosed in an ASX statement that it picked up 58,583 shares on Feb. 20, shelling out close to A$9.0 million at prices ranging from A$150.85 to A$154.07 apiece. The on-market buyback now totals around 3.45 million shares, with spending approaching A$654 million so far. The company’s repurchase plan, capped at up to US$750 million, remains set to run through June 30. UBS is handling the transactions as broker.
Separate filings revealed non-executive directors Constantine Saroukos and Cameron Price picked up rights via CSL’s director plan. According to the documents, the volume-weighted average price came in at A$152.492553.
CSL shares tumbled again, extending losses from earlier this month after the company posted an 81% plunge in first-half profit—hit by one-off charges and sluggish sales of its blood plasma products and vaccines. CEO Paul McKenzie exited in the aftermath. “I’m not prepared to accept that we can’t do better,” interim chief Gordon Naylor told analysts, as CSL maintained its full-year forecast. Reuters
The stock remains vulnerable if the plasma segment fails to provide the second-half boost outlined in guidance, or if there’s another shake-up in policy or pricing in major markets. A buyback might support the share price, but it won’t fix earnings by itself.
Markets are closed, so traders turn their focus to Tuesday. They’ll be looking for signs of continued selling or a rebound, and any new tariff headlines that might shake up risk appetite yet again.
CSL shares go ex-dividend March 10, so anyone buying from that date won’t get the interim payout. The record date falls on March 11, and cash hits accounts April 9. Looking ahead, the next key date is August 18 for full-year results and the final dividend decision.
